https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/50090-1659/
50090-1659 Ondansetron - CanMED: NDC
CanMED: NDC. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies.
ondansetronndc
https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/50090-7369/
50090-7369 Prednisone - CanMED: NDC
CanMED: NDC. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies.
prednisonendc
https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/50090-0942/
50090-0942 Tamoxifen Citrate - CanMED: NDC
CanMED: NDC. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies.
tamoxifen citratendc
https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/50090-2285/
50090-2285 Dutasteride - CanMED: NDC
CanMED: NDC. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies.
dutasteridendc
https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/50090-1941/
50090-1941 Estradiol - CanMED: NDC
CanMED: NDC. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies.
estradiolndc
https://feedly.com/cve/CVE-2025-50090
CVE-2025-50090 - Exploits & Severity - Feedly
Vulnerability in the Oracle Applications Framework product of Oracle E-Business Suite (component: Personalization). Supported versions that are affected are...
cveexploitsseverityfeedly
https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/50090-1936/
50090-1936 Finasteride - CanMED: NDC
CanMED: NDC. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies.
finasteridendc